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Abstract
Background: Matrix-metalloproteinases (MMP) and cancer cell invasion are crucial for solid tumour metastasis. Important
signalling events triggered by inﬂammatory cytokines, such as tumour necrosis factor α (TNFα), include Src-kinase-dependent
activation of Akt and focal adhesion kinase (FAK) and phosphorylation of caveolin-1. Based on previous studies where we
demonstrated amide-type local anaesthetics block TNFα-induced Src activation in malignant cells, we hypothesized that local
anaestheticsmight also inhibit the activation and/or phosphorylation of Akt, FAK and caveolin-1, thus attenuatingMMP release
and invasion of malignant cells.
Methods: NCI-H838 lung adenocarcinoma cells were incubated with ropivacaine or lidocaine (1 nM-100 µM) in absence/
presence of TNFα (20 ng ml−1) for 20 min or 4 h, respectively. Activation/phosphorylation of Akt, FAK and caveolin-1 were
evaluated by Western blot, and MMP-9 secretion was determined by enzyme-linked immunosorbent assay. Tumour cell
migration (electrical wound-healing assay) and invasion were also assessed.
Results: Ropivacaine (1 nM–100 μM) and lidocaine (1–100 µM) signiﬁcantly reduced TNFα-induced activation/phosphorylation
of Akt, FAK and caveolin-1 in NCI-H838 cells. MMP-9 secretion triggered by TNFαwas signiﬁcantly attenuated by both lidocaine
and ropivacaine (half-maximal inhibitory concentration [IC50]=3.29×10
−6M for lidocaine; IC50=1.52×10
−10M for ropivacaine). The
TNFα-induced increase in invasion was completely blocked by both lidocaine (10 µM) and ropivacaine (1 µM).
Conclusions: At clinically relevant concentrations both ropivacaine and lidocaine blocked tumour cell invasion and
MMP-9 secretion by attenuating Src-dependent inﬂammatory signalling events. Although determined entirely in vitro,
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these ﬁndings provide signiﬁcant insight into the potential mechanism by which local anaesthetics might diminish
metastasis.
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Editor’s key points
• Anaesthetic techniques may have an impact on outcome
from cancer surgery.
• Local anaesthetics have anti-inﬂammatory effects which
may impact upon cancer cell invasion.
• Lung adenocarcinoma cells were exposed to ropivacaine or
lidocaine at clinically relevant concentrations.
• Both local anaesthetics blocked tumour cell invasion and
metalloproteinase expression via effects on Src signalling.
• This provides some insight into the mechanisms behind
the effects of local anaesthetics on cancer cell invasion.
There is conﬂicting evidence regarding the effect of anaesthesia
technique and patient outcome after cancer surgery.1 Retrospective
analyses indicate the perioperative use of regional anaesthesia
using amide-linked local anaesthetics (LAs) may decrease cancer
recurrence and metastasis in these patients.2–4 Anti-inﬂammatory
effects of LAs in various epithelial and endothelial cell types are
well known.5 6 The fact that LAs have anti-inﬂammatory properties
in malignant cells lead to our recent observations that amide-type
LAs inhibit the activation of inﬂammatory Src tyrosine protein
kinase (Src), a critical mediator of endothelial hyperpermeability
and also cancer cell extravasation and metastasis.7 8
Matrix-metalloproteinases (MMPs) are important in the patho-
genesis of new metastatic sites from solid tumours as these en-
zymes degrade the extracellular matrix and basal lamina, thus
allowing malignant cells to enter or escape the primary tumour,
enter the circulation, and extravasate to form satellite lesions.9 10
De novo synthesis of MMPs [e.g. due to stimulation with tumour
necrosis factor α (TNFα)], largely depends onSrc-dependent activa-
tion of Akt and focal adhesion kinase (FAK) and phosphorylation
of caveolin-1 (Cav-1) by Src,11 signalling pathways which are also
required for cancer cell migration.12–14
In the present study, we tested the hypothesis that amide-
type local anaesthetics such as lidocaine and ropivacaine inhibit
TNFα-induced Akt and FAK activation and Src-dependent Cav-1
phosphorylation, thus attenuating MMP-9 secretion, migration,
and invasion of lung adenocarcinoma cells (Fig. 1).
Methods
Cell culture
Human NCI-H838 lung adenocarcinoma cells (CRL-5844, ATCC,
Rockville, MD) were cultured as previously described.7 All cells
weremaintained in 5% CO2 and 95% room air in awater-jacketed
37°C incubator.
Experimental procedure
NCI-H838cellmonolayerswere incubatedwithTNFα (Gibco Invitro-
gen, Carlsbad, CA, ﬁnal concentration 20 ngml−1) in the absence or
presence of lidocaine (lidocaine-HCl 2%, APP Pharmaceuticals,
Schaumburg, IL) or ropivacaine (Naropin® 0.5%, APP Pharmaceuti-
cals) at concentrations ranging from 1 pM–100 µM, depending on
the experiment. Incubation times varied between 20min forWest-
ern blot analysis (Akt, FAK and Cav-1) and 4 h for determination of
MMP-9 secretion. For some experiments, cells were pre-treated
withwortmannin (100 nM, SigmaAldrich, St. Louis, MO), an inhibi-
torofphosphoinositide-3kinase (PI3K),which is required for theac-
tivation of Akt, or the speciﬁc FAK inhibitor FI 14 (5 µM, Tocris
Bioscience, Minneapolis, MN) (Fig. 1).
Cell harvest and lysis
After indicated incubation times, cells were harvested and lysed
as described previously.15 Total protein concentration was deter-
mined using the DC Protein Assay Kit (BioRad, Hercules, CA) in
accordance with the manufacturer’s instructions. Immuno-
globulin G was used for the generation of a standard curve.
Western blot analysis
Whole cell lysates were subjected to Western blot analysis follow-
ing a published protocol.16Antibodies against FAK, phosphorylated
at tyrosine 397 (pY397), total FAK, glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), and total Akt were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA), against phospho-tyrosine 14
(pY14) Cav-1, total Cav-1, and β-actin fromBDBiosciences (Franklin
Lakes, NJ), and for Akt, phosphorylated at threonine 308 (pT308),
from Cell Signaling Technology (Danvers, MA).
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Fig 1 Summary of proposed mechanism by which amide-linked local
anaesthetics inhibit cancer cell invasion and metastasis. As demonstrated
previously, local anaesthetics (LA) block tumour necrosis factor α (TNFα)-
induced activation of Src tyrosine protein kinase (Src) by inhibiting signal
propogation downstream of TNF receptor 1 (TNF-R1).7 8 Through this
mechanism, amide-linked LAs indirectly prevent activation of Akt kinase
(Akt), phosphorylation of caveolin-1, and activation of focal adhesion
kinase (FAK). These signalling steps are crucial during metastasis, as they
promote cancer cell migration by regulating the cytoskeleton and are
necessary for the secretion of matrix-metalloproteinases (MMP), thus
enabling the cells to break up the basal lamina and the extracellular
matrix (ECM) and further invade into the surrounding tissue.
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Enzyme-linked immunosorbent assay (ELISA)
The concentration of MMP-9 in cell culture supernatant was
determined using the human MMP-9 DuoSet from R&D Systems
(Minneapolis, MN) in accordance with the manufacturer’s
instructions. The total amount of MMP-9 secreted by the cells
in each well was calculated from the ELISA values (pg ml−1) and
normalized to the amount of protein (pg mg−1 protein) found in
whole cell lysates.
Electrical wound-healing assay
NCI-H838 lung cancer cells were grown to conﬂuence on gold-
plated microelectrodes (ECIS cultureware; Applied Biophysics,
Troy, NY) coated with 0.2% gelatin (Sigma-Aldrich, St. Louis,
MO). Electrical impedance measured over time across the mono-
layer at 1 V, 4000 Hz with the Electric Cell-Substrate Impedance
Sensing (ECIS) system (Applied Biophysics), was used to calculate
transepithelial resistance. After an equilibration period of 30min,
TNFα (ﬁnal concentration 20 ng ml−1) was added in absence or
presence of lidocaine (10 µM) or ropivacaine (1 µM). After that,
cells growing in the middle of the gold electrode (i.e. on the
small active electrode) were injured via the application of 2.5 V
at 40 000 Hz for 10 s, leading to an immediate decrease in transe-
pithelial resistance.17 Recovery of transepithelial resistance after
electrical injury was used as a surrogate for cell migration.17 For
some experiments, cells were pre-treated for 30 min before the
addition of TNFαwith either wortmannin (100 nM) or FAK inhibi-
tor (FI) 14 (5 µM).
In vitro invasion assay
Transwell inserts with a polycarbonatemembranewith 8 μmpore
size (Falcon® Permeable Support, BD Biosciences) were coated
with 20 µl of Matrigel® (Growth Factor Reduced, from Corning,
TewksburyMA). NCI-H838 cells were suspended in RPMI-1640me-
diumwith 0% FBS and treated with either lidocaine (10 µM) or ro-
pivacaine (1 µM) in the absence or presence of TNFα (20 ng ml−1).
The cell suspension was inoculated in the upper chamber of the
Transwell, which was then inserted into a 24-well cell culture
plate (TPP Techno Plastic Products, Trasadingen, Switzerland).
The bottom chamber of the system was pre-ﬁlled with RPMI-
1640 medium supplemented with 10% FBS plus TNFα and LA as
in each corresponding upper chamber. Cells were allowed to in-
vade into the Matrigel-coated membrane for 6 h. Non-invading
cells were removed, invading cells were ﬁxedwith 2% paraformal-
dehyde solution (Kantonsapotheke Zurich, Zurich, Switzerland)
and stained with 4′,6-diamidino-2-phenylindole (DAPI, Life Tech-
nologies, Zug, Switzerland). Membranes were mounted on glass
slides for microscopy and quantitative image analysis. Images
were acquired at 20× magniﬁcation using a Leica DM6000Bmicro-
scope equipped with a DFC350FX camera and Leica Application
Suite Advanced Fluorescence software, Version 3.x for Windows
(all fromLeicaMicrosystems, Heerbrugg, Switzerland). Semi-auto-
mated counting of cell nuclei stained with DAPI was carried out
using the ImageJ software, Version 1.47v for Mac (http://imagej.
nih.gov/ij). Eight ﬁelds of view (0.2 mm2 each) were quantiﬁed
per slide and averaged for further analysis.
Statistical analysis
Normal distribution was assessed using Shapiro–Wilk testing.
Normally distributed data of transepithelial resistance were
analysed by one-way ANOVA. Non-normally distributed data
(invasion) were analysed with non-parametric testing (Kruskal-
Wallis and subsequent Mann-Whitney U-tests) with post hoc
corrections using the Simes-Hochberg method in order to keep
the family-wise error rate below 0.05. All other data were evalu-
ated with two-way ANOVA with the local anaesthetic (or other
treatments) and the absence or presence of TNFα as factors to
be tested, whereas we report the F ratio with the degrees of free-
dom for each of these factors and for the interaction between
them. Bonferroni post hoc testing was conducted to detect differ-
ences between groups. The exact number of experiments is indi-
cated in the respective ﬁgure legend. All tests were performed
two-sided and non-blinded using GraphPad Prism software
for Mac, Version 6 (GraphPad Software). A p-value of <0.05 was
considered statistically signiﬁcant.
The half-maximal inhibitory concentration (IC50)
18 was
assessed for lidocaine and ropivacaine on TNFα-induced MMP-
9 secretion by NCI-H838 lung cancer cells by plotting the MMP-9
concentration against the (logarithmic) concentration of the local
anaesthetic. Curve ﬁtting (Hill slope ﬁxed at −1.0) was conducted
using non-linear regression analysiswith the following equation:
Y ¼ Bottomþ ðTop BottomÞ
1þ 10ðXLogIC50Þ :
Results reported in Table 1 are values with 95% conﬁdence inter-
val (CI, for IC50, top, and bottom).
Results
Cytotoxic effects of local anaesthetics at the concentrations used
were excluded in a previous study.7
Representative Western blots of the activated form of Akt,
phosphorylated at threonine 308 (pT308 Akt), total Akt, and
GAPDH are shown in Figure 2A and B. Quantitative densitometry
analysis revealed a 2.6-fold increase in Akt activation after treat-
ment with TNFα alone compared with untreated cells (2.71 [
0.92] Figure 2Ci and 2.35 [0.45], Figure 2 Cii, respectively). In the
experiments involving lidocaine, analysis with two-way ANOVA
showed a signiﬁcant effect of TNFα (F(1,90)=17.55, P<0.001). Post
hoc analysis revealed a signiﬁcant reduction in TNFα-induced
Akt activation in presence of lidocaine at a concentration of 1
µM (p=0.03), Figure 2Ci. As shown in Figure 2Cii, TNFα-induced
Akt activation was also signiﬁcantly blocked by ropivacaine at 1
nM (p=0.03).
The same samples were also evaluated for FAK phosphoryl-
ation at tyrosine 397 (pY397 FAK) as compared to the total
Table 1 Inhibitory properties of lidocaine and ropivacaine on TNFα-induced MMP-9 secretion by NCI-H838 lung adenocarcinoma cells. IC50,
half maximal inhibitory concentration; CI, conﬁdence interval
Drug IC50 [M] (95% CI) Bottom (95% CI) Top (95% CI)
Lidocaine 3.291×10−6 (1.358×10−6–7.978×10−6) 37.62 (25.5–49.74) 114.0 (103.3–124.7)
Ropivacaine 1.521×10−10 (4.155×10−11–5.57×10−10) 70.15 (57.72–82.58) 126.9 (115.3–138.5)
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amount of FAK protein (Fig. 2D and E). We again observed a sig-
niﬁcant effect of TNFα on FAK phosphorylation in both sets of ex-
periments (F(1,69)=15.81 P<0.001 for lidocaine experiments),
Figure 2Fi; (F(1,60)=23.14 P<0.001 for ropivacaine experiments,
Fig. 2Fii). The effect of the two different LAs reached statistical
signiﬁcance by two-way ANOVA (F(4,69)=4.07 P=0.005) for lido-
caine experiments, Figure 2Fi. Post hoc analysis was comparable
with those observed with Akt: 10 µM lidocaine attenuated
TNFα-induced FAK activation by 51% [25%] (P=0.04) and ropiva-
caine completely abolished the TNFα-induced increase in
pY397 FAK at a concentration of 1 nM (P=0.01). At higher concen-
trations (beginning at 10 µM) and in absence of TNFα, ropivacaine
signiﬁcantly decreased FAK phosphorylation below baseline va-
lues (P=0.01, Fig. 2Fii).
We also assessed the effect of lidocaine and ropivacaine on
TNFα-induced Cav-1 phosphorylation at tyrosine 14 via Western
blot (pY14 Cav-1, Fig 3A and B). TNFα signiﬁcantly increased
pY14 Cav-1 by 75% [51%], (F(1,60)=4.22, P=0.04, Fig. 3Ci) and 49%
[36%] (F(1,65)=5.42, P=0.02, Fig. 3Cii), respectively. It also became evi-
dent that both LAs completely blocked TNFα-induced Cav-1
Fig 2 () RepresentativeWestern blots of Akt phosphorylated at threonine 308 (pT308 Akt, row 1), total Akt (row 2), and GAPDH, (row 3) after treatment with either (i)
lidocaine or (ii) ropivacaine (1 nM–100 µM) for 20 min in absence () or presence () of tumour necrosis factor α (TNFα) () Quantitative analysis of densitometry of
Western blots showing the ratio of pT308 Akt over total Akt in NCI-H838 cells treated with (i) lidocaine or (ii) ropivacaine compared with untreated cells (set as 1.0,
dashed line) in absence (green bars) or presence (blue bars) of TNFα (20 ngml−1). Data shownaremean () (n=10 for lidocaine; n=7 for ropivacaine; *P<0.05 compared
with TNFα alone. () RepresentativeWestern blots of FAK phosphorylated at tyrosine 397 (pY397 FAK, row 1), total FAK (row 2), and GAPDH (row 3) after treatment
with either (i) lidocaine or (ii) ropivacaine (1 nM–100 µM) alone for 20min, or () after treatmentwith TNFα in absence or presence of (i) ropivacaine or (ii.) lidocaine (1
nM–100 µM) for 20 min. ( ) Quantitative analysis of densitometry of Western blots showing the ratio of pY397 FAK over total FAK in NCI-H838 cells treated with (i.)
lidocaine or (ii.) ropivacaine compared with untreated cells (set as 1.0, dashed line) in absence (blue bars) or presence (green bars) of TNFα (20 ngml−1). Data shown
are mean (), n=8 for lidocaine, n=7 for ropivacaine; *P<0.05 compared with TNFα alone, #P<0.05 vs. control.
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Fig 3 RepresentativeWestern blots of caveolin-1 (Cav-1) phosphorylated at tyrosine 14 (pY14 Cav-1, row 1), total Cav-1 (row 2), and either (i.) β-actin or (ii.) (GAPDH,
row 3 respectively) after treatment with either (i.) lidocaine or (ii.) ropivacaine (1 nM–100 µM) alone for 20min (), or following () treatment with TNFα in absence or
presence of (i.) ropivacaine or (ii.) lidocaine (1 nM–100 µM) for 20min. () Quantitative analysis of densitometry ofWestern blots showing the ratio of pY14 Cav-1 over
total Cav-1 in NCI-H838 cells treated with (i.) lidocaine or (ii.) ropivacaine compared with untreated cells (set as 1.0, dashed line) in absence (green bars) or presence
(blue bars) of TNFα (20 ng ml−1). Data shown are mean (), n=7 for lidocaine; n=8 for ropivacaine; *P<0.05 compared with TNFα alone.
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phosphorylation at concentrations of 1 µM (P=0.002 for lidocaine,
P=0.004 for ropivacaine).
Non-linear curve ﬁtting was used to determine IC50 values of
lidocaine and ropivacaine on TNFα-induced MMP-9 secretion as
shown in Table 1: the IC50 for lidocaine was 3.29 µM (95% CI,
1.36–7.98 µM) with a maximum effect of 62% (95% CI, 51–75%)
whereas ropivacaine had a lower IC50 (152 pM, 95% CI, 42–557
pM) and a lower maximum effect of 30% (95% CI, 17–42%, all
Table 1). NCI-H838 cells pre-treated with either wortmannin
(100 nM) or FI 14 (5 µM) had signiﬁcantly lower TNFα-induced
MMP-9 secretion of 37% [7%] and 52% [5%], (P<0.001 compared
with TNFα alone for both, all Fig. 4A).
Resistance values measured over NCI-H838 monolayers were
normalized to baseline values and plotted against time as shown
in Fig. 4. Treatment with TNFα resulted in complete restoration
of monolayer integrity (96% [12%] of pre-injured baseline resist-
ance) compared with untreated cells in which the resistance
was still 23 [13%] below basal at the 3 h time point (Fig. 4; one-
wayANOVA, P=0.006). Lidocaine and ropivacaine both completely
abolished TNFα-induced migration and recovery of barrier prop-
erties in the presence of lidocaine, (P<0.001); or ropivacaine,
(P=0.01) compared with TNFα alone. Pre-treatment with either
wortmannin or FI 14 also decreased the restoration of barrier
properties compared with TNFα alone (both P<0.001 Fig. 4).
Supplementary data, Figure 1 shows representative micro-
scopic images ofMatrigel®-coatedmembranes after the invasion
assay. Counting of the number of cells per ﬁeld of view reveals a
signiﬁcant increase in invasion when cells were stimulated with
TNFα (median 125 [minimum–maximum 88–160] cells/ﬁeld vs
control, 64 [53–71] cells/ﬁeld, P<0.001, Fig. 5). Incubation of the
cells with ropivacaine or lidocaine alone did not alter the number
of invading cells compared with unstimulated cells (data not
shown). However, both lidocaine (10 µM) and ropivacaine (1 µM)
completely blockedTNFα-induced invasion of tumour cells, simi-
lar to that observed in presence of wortmannin or FI 14 (P<0.01 vs
TNFα alone for all comparisons, Fig. 5).
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in cell culture supernatants of NCI-H838 cells treated with 100 nM
Wortmannin (an inhibitor of phosphoinositide-3 kinase) or 5 µM FI 14 in
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Normalized resistance of NCI-H838 lung cancer cell monolayers over time
after electrical injury with 2.5 V at 40 000 Hz for 10s (indicated by arrow).
Treatment with either TNFα (20 ng ml−1, green), TNFα+lidocaine (10 µM,
pink), TNFα+ropivacaine (1 µM, gold), TNFα+wortmannin (100 nM,
turquoise, pre-treatment for 30 min before addition of TNFα), TNFα+FI 14
(5 µM, orange, pre-treatment for 30 min before addition of TNFα), or
vehicle (control, blue). Data shown are mean () of normalized
resistance. () Quantiﬁcation of normalized resistance at 3 h. Data shown
are mean (); untreated cells (blue bar), TNFα alone (green bar), lidocaine
at 10 µM (pink bar), TNFα+ropivacaine at 1 µM (gold bar), TNFα
+wortmannin (turquoise bar) and TNFα+FI 14 (orange bar); n=10 for
control, TNFα, TNFα+ropivacaine, TNFα+lidocaine; n=8 for TNFα
+wortmannin, TNFα+FI 14; #P<0.05 vs untreated cells, *P<0.05 compared
with TNFα alone.
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Fig 5Quantitative analysis of the number of invading cells found per ﬁeld of
view in DAPI stained images of Matrigel coated membranes. Cells were
treated with and without TNF plus lidocaine, ropivacaine, wortmannin or
FI 14. Data presented as boxplots showing the median, with interquartile
and full range. N=5, whereas the values for each slide were calculated as
the mean of 8 ﬁelds of view. #P<0.05 vs untreated cells, *P<0.05 compared
with TNFα alone.
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Discussion
In this study,we evaluated the effect of lidocaine and ropivacaine
onTNFα-induced, Src-dependent inﬂammatory signalling events
in malignant cells, namely activation of Akt and FAK and phos-
phorylation of Cav-1.
As hypothesized, these signalling events were blocked in
presence of the amide-linked LAs. We then also linked inhibition
of this inﬂammatory signalling downstream of TNFα and Src to
function, assessing the effect of LAs on MMP-9 production, mi-
gration, and invasion of H838 cells, further elucidating a potential
mechanism by which local anaesthetics might be able to attenu-
ate metastasis of solid epithelial tumours.
Mechanisms similar to inﬂammatory processes may play an
important role in the development, growth, and metastasis of
solid tumours.19–21 We have previously shown that amide-
linked local anaesthetics, such as lidocaine and ropivacaine, in-
hibit TNFα-induced activation of Src by blocking the early
propagation of signalling at the level of TNFα receptor-1
(TNF-R1).7 8 Activated Src functions to increase vascular perme-
ability,22 cancer and inﬂammatory cell adhesion to the endothe-
lium, and cancer cell migration. Additionally, Src is involved in
signalling epithelial-to-mesenchymal transformation and ex-
travasation of cancer cells, processes that are necessary for
solid tumour metastasis.19 23
The release of MMPs by neutrophils and malignant cells alike
is known to contribute to tumour growth and metastasis by de-
grading the extracellular matrix and breaking up the basal lam-
ina, thereby enabling cancer cells to enter and then exit the
circulation at a remote location.9 10 TNFα-induced expression
of MMPs by malignant cells is Src-dependent and involves the
PI3 K/Akt pathway.11 Activation of Akt by PI3K is Src-dependent
and involved in numerous downstream signalling events that
contribute to cancer cell growth, proliferation and survival and
has therefore become a very interesting protein for targeted ther-
apies.24 The results of our study clearly show that both lidocaine
and ropivacaine signiﬁcantly inhibit Akt activation in NCI-H838
non-small cell lung cancer (NSCLC) cells, thus attenuating
MMP-9 production.
Cav-1 is a primary Src substrate22 and Src-dependent Cav-1
Y14 phosphorylation is important for migration of (malignant)
cells via the regulation of focal adhesion dynamics and assem-
bly,12 14 which also involves the PI3K/Akt pathway.25 pY14-Cav-1
promotes tumour growth whereas loss of Cav-1 expression in
either the tumour microenvironment or cancer cells per se
leads to a signiﬁcant increase in invasiveness and overall
worse prognosis.26–28 As we have previously shown that tyro-
sine phosphorylation of Cav-1 promotes its degradation,16 re-
duction of pY14 Cav-1 as seen in our study may be a
mechanism by which the LAs reduce the metastatic potential
of malignant cells.
FAK is themost important kinase in focal adhesion signalling
and its activation is not only PI3K- and Src-dependent,29 30 but
also crucial for cell orientation, actin cytoskeletal assembly/re-
organization, and ultimately cancer cell migration.12 13 31 The
results from our study conﬁrm these previous ﬁndings. We
showed that enhanced cancer cell migration induced by TNFα
was impaired by the PI3K inhibitor wortmannin, the speciﬁc
FAK inhibitor FI 14, and importantly, lidocaine and ropivacaine
had a similar effect.
In order to combine ﬁndings on the effect of LAs on TNFα-
signalling, migration, and MMP secretion, we assessed the im-
pact of lidocaine and ropivacaine on tumour cell invasion into a
collagen-rich environment in vitro. We demonstrated that the
amide-linked local anaesthetics lidocaine and ropivacaine were
able to completelymitigate TNFα-induced enhancement in inva-
sion and showed that inhibition of Akt activation and FAK had
the same effect. These ﬁndings are in accordance with results
from experiments conducted by Baptista and colleagues32,
where ropivacaine was also demonstrated to inhibit invasion of
metastatic colon cancer cells (SW620), as a result of an inhibition
of the Nav1.5 subset of voltage-gated sodium channels (VGSC).
However, we previously showed that lidocaine and ropivacaine
(amide-linked LAs), but not chloroprocaine (ester-type LA), in-
hibit TNFα-induced Src activation and downstream signalling
in NCI-H838 lung cancer cells independently of VGSC blockade,7
further supporting our hypothesis that LAs exhibit anti-
inﬂammatory and anti-metastatic effects, by blocking TNFα
signalling at the level of its receptor, TNF-R1.8
Taken togetherwith results of PI3K inhibitor wortmannin and
FAK inhibitor FI 14, the observed attenuation of cancer cell inva-
sion by lidocaine and ropivacaine is likely to be as a result of the
blockade of Src-dependent Akt and FAK activation and of Cav-1
phosphorylation.
In summary, cancer dissemination is a multi-step process
where many cellular and molecular regulatory mechanisms
may be targets for therapeutic interventions. This study clearly
demonstrates the importance of the blockade of the Src pathway
by clinically relevant concentrations of amide LAs and—most im-
portantly—explores this pathway further downstream, linking
the interference with this particular pathway to the invasion of
malignant cells.
Although determined entirely in vitro, the current study pro-
vides new and signiﬁcant insight into a potential mechanism
by which amide-LAs might attenuate metastasis.
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